Key points are not available for this paper at this time.
Peter Reuter’s scholarship reshaped drug policy analysis by treating drugs as commodities traded by rational actors. He showed how prohibition creates a risk–price premium and urged analytic humility, warning that hidden-market opacity and cross-context variation make universal policy claims fragile. This paper maps Reuter’s intellectual trajectory and his systematic approach to evaluation. It highlights his shift away from single metrics (seizures, prevalence) towards a portfolio of outcomes: public health harms, market-generated harms (violence, corruption), and control harms (incarceration, inequality), and explains why causal inference is especially tenuous when indicators are noisy. Drawing on evidence across eras and substances, it describes mechanisms behind diminishing returns to supply-side control: upstream costs are small relative to retail markups, enforcement functions as a stochastic tax, and traffickers adapt in ways that blunt effects on price and availability. The paper derives practical implications for reform and concludes with Reuter’s roles in institution-building and mentorship.
Alberto Aziani (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: